Nordquist E, Zhao M, Kumar A, MacKerell Jr A
J Chem Inf Model. 2024; 64(19):7743-7757.
PMID: 39283165
PMC: 11473228.
DOI: 10.1021/acs.jcim.4c01189.
Zhu Y, Alqahtani S, Hu X
Molecules. 2024; 29(2).
PMID: 38257217
PMC: 11154270.
DOI: 10.3390/molecules29020304.
Lukasik P, Baranowska-Bosiacka I, Kulczycka K, Gutowska I
Int J Mol Sci. 2021; 22(6).
PMID: 33802080
PMC: 8001317.
DOI: 10.3390/ijms22062806.
Talapati S, Nataraj V, Pothuganti M, Gore S, Ramachandra M, Antony T
Acta Crystallogr F Struct Biol Commun. 2020; 76(Pt 8):350-356.
PMID: 32744246
PMC: 7397463.
DOI: 10.1107/S2053230X20009243.
Frame S, Saladino C, MacKay C, Atrash B, Sheldrake P, McDonald E
PLoS One. 2020; 15(7):e0234103.
PMID: 32645016
PMC: 7347136.
DOI: 10.1371/journal.pone.0234103.
Identification and characterization of fragment binding sites for allosteric ligand design using the site identification by ligand competitive saturation hotspots approach (SILCS-Hotspots).
MacKerell Jr A, Jo S, Lakkaraju S, Lind C, Yu W
Biochim Biophys Acta Gen Subj. 2020; 1864(4):129519.
PMID: 31911242
PMC: 7029399.
DOI: 10.1016/j.bbagen.2020.129519.
Identification of novel CDK2 inhibitors by a multistage virtual screening method based on SVM, pharmacophore and docking model.
Liang J, Wang M, Wang S, Li S, Li W, Meng F
J Enzyme Inhib Med Chem. 2019; 35(1):235-244.
PMID: 31760818
PMC: 6882486.
DOI: 10.1080/14756366.2019.1693702.
Aspirin metabolites 2,3‑DHBA and 2,5‑DHBA inhibit cancer cell growth: Implications in colorectal cancer prevention.
Sankaranarayanan R, Valiveti C, Dachineni R, Kumar D, Lick T, Bhat G
Mol Med Rep. 2019; 21(1):20-34.
PMID: 31746356
PMC: 6896348.
DOI: 10.3892/mmr.2019.10822.
The Flavonoid Metabolite 2,4,6-Trihydroxybenzoic Acid Is a CDK Inhibitor and an Anti-Proliferative Agent: A Potential Role in Cancer Prevention.
Sankaranarayanan R, Valiveti C, Kumar D, Van Slambrouck S, Kesharwani S, Seefeldt T
Cancers (Basel). 2019; 11(3).
PMID: 30917530
PMC: 6468648.
DOI: 10.3390/cancers11030427.
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
Sonawane Y, Taylor M, Napoleon J, Rana S, Contreras J, Natarajan A
J Med Chem. 2016; 59(19):8667-8684.
PMID: 27171036
PMC: 5636177.
DOI: 10.1021/acs.jmedchem.6b00150.
Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones.
Grigoroudis A, McInnes C, Premnath P, Kontopidis G
Protein Expr Purif. 2015; 113:8-16.
PMID: 25956535
PMC: 4456239.
DOI: 10.1016/j.pep.2015.01.013.
The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins.
Kozakov D, Grove L, Hall D, Bohnuud T, Mottarella S, Luo L
Nat Protoc. 2015; 10(5):733-55.
PMID: 25855957
PMC: 4762777.
DOI: 10.1038/nprot.2015.043.
UFSRAT: Ultra-fast Shape Recognition with Atom Types--the discovery of novel bioactive small molecular scaffolds for FKBP12 and 11βHSD1.
Shave S, Blackburn E, Adie J, Houston D, Auer M, Webster S
PLoS One. 2015; 10(2):e0116570.
PMID: 25659145
PMC: 4319890.
DOI: 10.1371/journal.pone.0116570.
Investigation of the flexibility of protein kinases implicated in the pathology of Alzheimer's disease.
Mazanetz M, Laughton C, Fischer P
Molecules. 2014; 19(7):9134-59.
PMID: 24983862
PMC: 6270768.
DOI: 10.3390/molecules19079134.
Drug targets for cell cycle dysregulators in leukemogenesis: in silico docking studies.
Jayaraman A, Jamil K
PLoS One. 2014; 9(1):e86310.
PMID: 24454966
PMC: 3893288.
DOI: 10.1371/journal.pone.0086310.
Crystal structure of human cyclin-dependent kinase-2 complex with MK2 inhibitor TEI-I01800: insight into the selectivity.
Fujino A, Fukushima K, Kubota T, Kosugi T, Takimoto-Kamimura M
J Synchrotron Radiat. 2013; 20(Pt 6):905-9.
PMID: 24121337
PMC: 3795553.
DOI: 10.1107/S0909049513020736.
Sanjeevini: a freely accessible web-server for target directed lead molecule discovery.
Jayaram B, Singh T, Mukherjee G, Mathur A, Shekhar S, Shekhar V
BMC Bioinformatics. 2013; 13 Suppl 17:S7.
PMID: 23282245
PMC: 3521208.
DOI: 10.1186/1471-2105-13-S17-S7.
Discovery of a new class of inhibitors for the protein arginine deiminase type 4 (PAD4) by structure-based virtual screening.
Teo C, Shave S, Chor A, Bakar Salleh A, Rahman M, Walkinshaw M
BMC Bioinformatics. 2013; 13 Suppl 17:S4.
PMID: 23282142
PMC: 3521205.
DOI: 10.1186/1471-2105-13-S17-S4.
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Hole A, Baumli S, Shao H, Shi S, Huang S, Pepper C
J Med Chem. 2012; 56(3):660-70.
PMID: 23252711
PMC: 3579457.
DOI: 10.1021/jm301495v.
Analogs of N'-hydroxy-N-(4H,5H-naphtho[1,2-d]thiazol-2-yl)methanimidamide inhibit Mycobacterium tuberculosis methionine aminopeptidases.
Bhat S, Olaleye O, Meyer K, Shi W, Zhang Y, Liu J
Bioorg Med Chem. 2012; 20(14):4507-13.
PMID: 22704656
PMC: 3495175.
DOI: 10.1016/j.bmc.2012.05.022.